[go: up one dir, main page]

RU2019104870A - Комбинированный тест на наличие колоректального рака - Google Patents

Комбинированный тест на наличие колоректального рака Download PDF

Info

Publication number
RU2019104870A
RU2019104870A RU2019104870A RU2019104870A RU2019104870A RU 2019104870 A RU2019104870 A RU 2019104870A RU 2019104870 A RU2019104870 A RU 2019104870A RU 2019104870 A RU2019104870 A RU 2019104870A RU 2019104870 A RU2019104870 A RU 2019104870A
Authority
RU
Russia
Prior art keywords
patient
cell
colorectal cancer
free nucleosome
detecting
Prior art date
Application number
RU2019104870A
Other languages
English (en)
Other versions
RU2019104870A3 (ru
Inventor
Якоб Винсент МИКАЛЛЕФ
Ясон ТЕРРЕЛ
Original Assignee
Белджиан Волишн Спрл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Белджиан Волишн Спрл filed Critical Белджиан Волишн Спрл
Publication of RU2019104870A publication Critical patent/RU2019104870A/ru
Publication of RU2019104870A3 publication Critical patent/RU2019104870A3/ru

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/57535
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G01N33/57585
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875Nucleoproteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721Haemoglobin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/154Methylation markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Claims (11)

1. Способ обнаружения и/или скрининга колоректального рака (CRC), колоректальной аденомы или полипа у пациента, включающий:
(a) идентификацию пациента, имевшего положительный результат анализа фекалий на скрытую кровь; и
(b) обнаружение или измерение уровня одного или более элементов в образце крови, сыворотки или плазмы, полученном у пациента, при этом элемент выбирают из бесклеточной нуклеосомы, эпигенетического признака бесклеточной нуклеосомы, карциноэмбрионального антигена, биомаркера метаболизма железа или индуцируемого гипоксией фактора,
при этом результат, полученный на этапе (b), указывает на вероятность наличия у пациента колоректального рака (CRC), колоректальной аденомы или полипа.
2. Способ оценки пригодности пациента для колоноскопии, включающий:
(a) анализ фекалий на скрытую кровь для образца фекалий, полученного у пациента;
(b) обнаружение или измерение уровня одного или более элементов в образце крови, сыворотки или плазмы, полученном у пациента, при этом элемент выбирают из бесклеточной нуклеосомы, эпигенетического признака бесклеточной нуклеосомы, карциноэмбрионального антигена, биомаркера метаболизма железа или индуцируемого гипоксией фактора; и
(c) использование результата, полученного в (b), в качестве показателя пригодности пациента для колоноскопии.
3. Способ по любому из пп. 1 и 2, который дополнительно включает в себя использование численного результата анализа фекалий на скрытую кровь в качестве параметра на этапе (b).
4. Способ по любому из пп. 1-3, который дополнительно включает использование клинического параметра на этапе (b).
5. Способ по п. 4, в котором клинический параметр выбирают из возраста, пола и индекса массы тела (ИМТ).
RU2019104870A 2016-07-25 2017-07-25 Комбинированный тест на наличие колоректального рака RU2019104870A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1612815.9 2016-07-25
GBGB1612815.9A GB201612815D0 (en) 2016-07-25 2016-07-25 Novel combination test
PCT/EP2017/068754 WO2018019827A1 (en) 2016-07-25 2017-07-25 Combination test for colorectal cancer

Publications (2)

Publication Number Publication Date
RU2019104870A true RU2019104870A (ru) 2020-08-25
RU2019104870A3 RU2019104870A3 (ru) 2020-12-01

Family

ID=56894403

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019104870A RU2019104870A (ru) 2016-07-25 2017-07-25 Комбинированный тест на наличие колоректального рака

Country Status (16)

Country Link
US (1) US20200182875A1 (ru)
EP (1) EP3488238B1 (ru)
JP (1) JP6983221B2 (ru)
KR (1) KR102442803B1 (ru)
CN (1) CN109791154A (ru)
AU (1) AU2017301970B2 (ru)
BR (1) BR112019001384A2 (ru)
CA (1) CA3031580A1 (ru)
GB (1) GB201612815D0 (ru)
IL (1) IL264359B2 (ru)
MY (1) MY193895A (ru)
RU (1) RU2019104870A (ru)
SG (2) SG11201900329XA (ru)
TW (1) TWI776816B (ru)
WO (1) WO2018019827A1 (ru)
ZA (1) ZA201808601B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201906199D0 (en) * 2019-05-02 2019-06-19 Belgian Volition Sprl Method for the detection of cancer
WO2021024009A1 (en) * 2019-08-02 2021-02-11 Shanghai Yunxiang Medical Technology Co., Ltd. Methods and compositions for providing colon cancer assessment using protein biomarkers
CN112345766B (zh) * 2020-10-22 2024-02-02 中国工程物理研究院核物理与化学研究所 一种荧光-放射性联用的体外靶向筛选方法
TW202242146A (zh) * 2021-01-13 2022-11-01 比利時商比利時意志有限公司 肺癌的檢測方法
US20240118282A1 (en) * 2021-02-11 2024-04-11 Herbert A. Fritsche Kits and methods for detecting markers and determining the presence or risk of cancer
WO2024223947A1 (en) * 2023-04-28 2024-10-31 Belgian Volition Srl Use of cell free nucleosomes as biomarkers of carcinomas
CN116973572B (zh) * 2023-06-02 2025-03-07 东南大学附属中大医院 基于血、粪便铁蛋白检测评估肠屏障损伤严重程度的方法
CN116718775B (zh) * 2023-08-04 2023-10-27 天津迈基生物科技有限公司 一种检测结直肠癌的组合物、试纸及方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010089538A2 (en) * 2009-02-03 2010-08-12 Oncomethylome Sciences Sa Methods of detecting colorectal cancer
CN102460173A (zh) * 2009-04-14 2012-05-16 加利福尼亚大学董事会 组蛋白修饰用于癌症的临床诊断和预后
US8568984B2 (en) * 2010-02-19 2013-10-29 Philadelphia Health & Education Corporation Methods of diagnosing non-urinary tract diseases by detecting aberrant methylation
JP2012018119A (ja) * 2010-07-09 2012-01-26 Toray Ind Inc 大腸癌検出用マーカーおよびそれを用いた大腸癌検出方法
KR20140016230A (ko) * 2010-08-04 2014-02-07 시즐 바이오테크놀로지 리미티드 암의 진단 및 치료를 위한 방법 및 화합물
GB201115098D0 (en) * 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
HUE035855T2 (en) * 2011-12-07 2018-05-28 Belgian Volition Sprl Method for detecting nucleosome adducts
CN104411835B (zh) * 2012-05-11 2019-12-20 临床基因组学股份有限公司 用于结直肠癌的诊断性基因标记系列

Also Published As

Publication number Publication date
JP2019527361A (ja) 2019-09-26
EP3488238C0 (en) 2023-06-07
AU2017301970A1 (en) 2019-01-17
BR112019001384A2 (pt) 2019-04-30
SG10202100630SA (en) 2021-03-30
AU2017301970B2 (en) 2023-04-27
IL264359A (en) 2019-02-28
WO2018019827A1 (en) 2018-02-01
IL264359B2 (en) 2024-03-01
EP3488238B1 (en) 2023-06-07
IL264359B1 (en) 2023-11-01
CA3031580A1 (en) 2018-02-01
EP3488238A1 (en) 2019-05-29
CN109791154A (zh) 2019-05-21
MY193895A (en) 2022-10-31
KR102442803B1 (ko) 2022-09-15
SG11201900329XA (en) 2019-02-27
TWI776816B (zh) 2022-09-11
JP6983221B2 (ja) 2021-12-17
ZA201808601B (en) 2019-09-25
RU2019104870A3 (ru) 2020-12-01
US20200182875A1 (en) 2020-06-11
GB201612815D0 (en) 2016-09-07
KR20190039089A (ko) 2019-04-10
TW201804156A (zh) 2018-02-01

Similar Documents

Publication Publication Date Title
RU2019104870A (ru) Комбинированный тест на наличие колоректального рака
Bahadır et al. Applications of electrochemical immunosensors for early clinical diagnostics
Kaczor‐Urbanowicz et al. Emerging technologies for salivaomics in cancer detection
Bakirhan et al. Recent progress on the sensitive detection of cardiovascular disease markers by electrochemical-based biosensors
Qi et al. Circulating long non-coding RNAs in cancer: current status and future perspectives
Farzin et al. Recent advances in design of electrochemical affinity biosensors for low level detection of cancer protein biomarkers using nanomaterial-assisted signal enhancement strategies
Lee et al. Aptamer-based sandwich assay and its clinical outlooks for detecting lipocalin-2 in hepatocellular carcinoma (HCC)
Zhao et al. Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma
JP2008542703A5 (ru)
US20180080937A1 (en) Biomarker Panel For Diagnosing Cancer
RU2014112350A (ru) Способ детекции нуклеосом, содержащих нуклеотиды
JP2018504609A5 (ru)
JP2019527361A5 (ru)
Roe et al. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case–control study
JP2016500110A5 (ru)
Beretov et al. Proteomics for breast cancer urine biomarkers
JP2011526693A5 (ru)
Pardi et al. Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers?
JP2009538607A5 (ru)
Kammer et al. Noninvasive biomarkers for lung cancer diagnosis, where do we stand?
Bilegsaikhan et al. Circulating miR‐338‐5p is a potential diagnostic biomarker in colorectal cancer
Werner et al. Evaluation of the diagnostic value of 64 simultaneously measured autoantibodies for early detection of gastric cancer
JP2011508197A5 (ru)
WO2015100459A3 (en) Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
JP2018529931A5 (ru)